TY - JOUR
T1 - Potentiation of the growth inhibition activity of 2-({4-[4-(acridin-9-ylamino)phenylthio]phenyl}(2-hydroxyethyl)amino)ethan-1-ol (CK0402) by herceptin in SKBR-3 human breast cancer cells
AU - Sun, Yuan Wan
AU - Niu, Ting Kuang
AU - Yang, Jin Ming
AU - Kwon, Chul Hoon
AU - Chen, Kuen Yuan
AU - Chen, Kun Ming
PY - 2010/5
Y1 - 2010/5
N2 - The 9-aminoacridine derivative, 2-({4-[4-(acridin-9-ylamino)phenylthio]phenyl}(2-hydroxyethyl)amino)ethan-1-ol (CK0402) was selected as a potential anticancer agent among a series of sulfur-containing 9-aminoacridine analogues. CK0402 is a topoisomerase II inhibitor and has been shown to exert impressive anticancer activities in both in vitro and in vivo assays. In the present study, we tested the effects of CK0402 in a panel of established human breast cancer cells with varying ER and HER2/neu status. The ER(-) and HER2-overexpressing SKBR-3 cells were the most sensitive cells tested in growth inhibition to CK0402 treatment, and the growth inhibition was in a time- and concentration-dependent manner. In addition, CK0402 also induced stronger G2/M arrest, apoptosis and autophagy in SKBR-3 cells than in ER(+) and HER2(-) MC F-7 cells. To the best of our knowledge, CK0402 is the first 9-aminoacridine analogue to induce autophagy. These findings suggest that CK0402 may be effective against the more aggressive and malignant ER(-) and HER2-overexpressing breast cancer. Towards this end, we further demonstrated that the combination of CK0402 and Herceptin exhibited synergistic/additive cytotoxic effects in SKBR-3 cells using the median-effect/combination-index isobologram methodology (CICI value). Our results indicate that the combination of CK0402 and Herceptin may be a potential therapeutic option against the more aggressive ER(-) and HER2-overexpressing breast cancer.
AB - The 9-aminoacridine derivative, 2-({4-[4-(acridin-9-ylamino)phenylthio]phenyl}(2-hydroxyethyl)amino)ethan-1-ol (CK0402) was selected as a potential anticancer agent among a series of sulfur-containing 9-aminoacridine analogues. CK0402 is a topoisomerase II inhibitor and has been shown to exert impressive anticancer activities in both in vitro and in vivo assays. In the present study, we tested the effects of CK0402 in a panel of established human breast cancer cells with varying ER and HER2/neu status. The ER(-) and HER2-overexpressing SKBR-3 cells were the most sensitive cells tested in growth inhibition to CK0402 treatment, and the growth inhibition was in a time- and concentration-dependent manner. In addition, CK0402 also induced stronger G2/M arrest, apoptosis and autophagy in SKBR-3 cells than in ER(+) and HER2(-) MC F-7 cells. To the best of our knowledge, CK0402 is the first 9-aminoacridine analogue to induce autophagy. These findings suggest that CK0402 may be effective against the more aggressive and malignant ER(-) and HER2-overexpressing breast cancer. Towards this end, we further demonstrated that the combination of CK0402 and Herceptin exhibited synergistic/additive cytotoxic effects in SKBR-3 cells using the median-effect/combination-index isobologram methodology (CICI value). Our results indicate that the combination of CK0402 and Herceptin may be a potential therapeutic option against the more aggressive ER(-) and HER2-overexpressing breast cancer.
KW - 9-aminoacridines
KW - Apoptosis
KW - Autophagy
KW - HER2
KW - Topoisomerase II
UR - http://www.scopus.com/inward/record.url?scp=77956211456&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77956211456&partnerID=8YFLogxK
U2 - 10.3892/etm_00000081
DO - 10.3892/etm_00000081
M3 - Article
AN - SCOPUS:77956211456
SN - 1792-0981
VL - 1
SP - 513
EP - 518
JO - Experimental and Therapeutic Medicine
JF - Experimental and Therapeutic Medicine
IS - 3
ER -